The purpose of the study is to evaluate the utility of Ischemia Modified Albumin (IMA) for risk stratification in patients presenting with chest discomfort and possible ischemic heart disease, and to evaluate the diagnostic and prognostic implication for IMA for major adverse cardiac events.
Study Type
OBSERVATIONAL
Enrollment
1,250
Massachusetts General Hospital
Boston, Massachusetts, United States
Dartmouth Medical Center
Lebanon, New Hampshire, United States
Cleveland Clinic
Cleveland, Ohio, United States
Vanderbilt University
Nashville, Tennessee, United States
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Hamilton General Hospital
Hamilton, Ontario, Canada